Modern chromatographic and electrophoretic measurements of antidepressants and their metabolites in biofluids

Biomedical Chromatography

Volumn 25, Issue 1, 2011, Pages 164-198

  Plenis, Alina ^a   BaCzek, Tomasz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Antidepressants; Biofluids; CE; GC; HPLC; Metabolites

Indexed keywords

BIOMOLECULES; DRUG INTERACTIONS; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PATIENT MONITORING;

ANTIDEPRESSANT; BIOFLUIDS; CE; CONDITION; GC; HPLC; MEASUREMENTS OF; MECHANISM OF ACTION; SIDE EFFECT; THERAPEUTIC DRUG MONITORING;

METABOLITES;

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DRUG METABOLITE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LY 550408; LY 581920; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORCLOMIPRAMINE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

ANALYTIC METHOD; BODY FLUID; BRAIN TISSUE; CAPILLARY ELECTROPHORESIS; CAPILLARY ZONE ELECTROPHORESIS; CATION EXCHANGE; CHROMATOGRAPHY; COLLISIONALLY ACTIVATED DISSOCIATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HAIR LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ELECTROPHORESIS; FLUORESCENCE ANALYSIS; GAS CHROMATOGRAPHY; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; LIQUID PHASE MICROEXTRACTION; MASS SPECTROMETRY; MICELLAR ELECTROKINETIC CHROMATOGRAPHY; MICELLAR LIQUID CHROMATOGRAPHY; NONAQUEOUS CAPILLARY ELECTROPHORESIS; NONHUMAN; PLASMA; REVIEW; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; SOLVENT EXTRACTION; STEADY STATE; STRUCTURE ACTIVITY RELATION; TABLET; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 78650711417     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1558     Document Type: Review

References (179)

1. Albers LJ, Reista UCh, Vu RL, Fujimoto K, Ozdemir V, Helmeste D, Poland R and Tang SW. Effect of venlafaxine on imipramine metabolism. Psychiatry Research 2000; 96: 235-243.
2. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J and Chung MD. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Journal of Clinical Psychopharmacology 1997; 17: 284-291.
3. Amsterdam JD, Brunswick DJ, Potter WZ, Winokur A and Rickels K. Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients: lack of correlation with therapeutic response. Archives of General Psychiatry 1985; 42: 361-364.
4. Aturki Z, Scotti V, D'Orazio G, Rocco A, Raggi, MA and Fanali S. Enantioselective separation of the novel antidepressant mirtazapine and its main metabolites by CEC. Electrophoresis 2007; 28: 2717-2725.
5. Badenhorst D, Sutherland FCW, de Jager AD, Scanes T, Hundt HKL, Swart KJ and Hundt AF. Determination of doxepin and desmethyldoxepin in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2000; 742: 91-98.
6. Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J and Irvine J. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. Journal of Clinical Psychopharmacology 1997; 17:15-21.
7. Balant-Gorgia AE and Balant LP. Therapeutic drug monitoring, relevance during drug treatment of psychiatric disorders. CNS Drugs 1995; 4: 432-453.
8. Balant-Gorgia AE, Gex-Fabry M and Balant LP. Clinical pharmacokinetics of clomipramine. Clinical Pharmacokinetics 1991; 20: 447-462.
9. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical Pharmacokinetics 1996; 31: 444-469.
10. Bengtsson F, Lundmark J, Nordin C, Reis M and Walinder J. TDM of selective serotonin reuptake inhibitors treating depression in the elderly reduces drug doses and costs. Therapeutic Drug Monitoring 1997; 19: 579.
11. Bertucci C and Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Current Medicinal Chemistry 2002; 9: 1463-1481.
12. Berzas Nevado JJ, Villaseñor Llerena MJ, Guiberteau Cabanillas C and Rodríguez Robledo V. Screening of citalopram, fluoxetine and their metabolites in human urine samples by gas chromatography-mass spectrometry. A global robustness/ruggedness study. Journal of Chromatography A 2006; 1123: 130-133.
13. Bhatt J, Jangid A, Venkatesh G, Subbaiah G and Singh S. Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma. Journal of Chromatography B 2005; 829: 75-81.
14. Böer U, Noll Ch, Cierny I, Krause D, Hiemke Ch and Knepel W. A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: reversal of chronic psychosocial stress-induced increase in CRE/CREB-directed gene transcription in transgenic reporter gene mice. European Journal of Pharmacology 2010; 633: 33-38
15. Bose D, Martinavarro-Domínguez A, Gil-Agustí M, Carda-Broch S, Durgbanshi A, Capella-Peiró ME and Esteve-Romero J. Therapeutic monitoring of imipramine and desipramine by micellar liquid chromatography with direct injection and electrochemical detection. Biomedical Chromatography 2005a; 19: 343-349.
16. Bose D, Durgbanshi A, Martinavarro-Domínguez A, Capella-Peiro ME, Carda-Broch S, Esteve-Romero J and Gil-Agust M. Amitriptyline and nortriptyline serum determination by micellar liquid chromatography. Journal of Pharmacological and Toxicological Methods 2005b; 52: 323-329.
17. Breaud AR, Harlan R, Kozak M and Clarke W. A rapid and reliable method for the quantitation of tricyclic antidepressants in serum using HPLC-MS/MS. Clinical Biochemistry 2009; 42: 1300-1307.
18. Cantú MD, Hillebrand S, Costa Queiroz ME, Lanças FM and Carrilho E. Validation of non-aqueous capillary electrophoresis for simultaneous determination of four tricyclic antidepressants in pharmaceutical formulations and plasma samples. Journal of Chromatography B 2004; 799: 127-132.
19. Castaing N, Titier K, Receveur-Daurel M, Le-Déodic M, Le-Bars D, Moore N and Molimard M. Quantification of eight new antidepressants and five of their active metabolites in whole blood by high-performance liquid chromatography-tandem mass spectrometry. Journal of Analytical Toxicology 2007; 31: 334-341.
20. Charlier C, Pinto E, Ansseau M and Plomteux G. Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. Journal of Psychopharmacology 2002; 16: 369-372.
21. Chauhan B, Rani S, Guttikar S, Zope A, Jadon N and Padh H. Analytical method development and validation of mianserin hydrochloride and its metabolite in human plasma by LC-MS. Journal of Chromatography B 2005; 823: 69-74.
22. Chen CC, Shou-Mei Wu SM, Huang YH, Ko WK, Kou HS and Wu HL. On-line field-amplified sample stacking in capillary electrophoresis for analysis of amitriptyline and its metabolite nortriptyline in plasma. Analytica Chimica Acta 2004; 517: 103-110.
23. Cherkaoui S, Rudaz S, Varesio E and Veuthey JL. On-line capillary electrophoresis-electrospray mass spectrometry for the stereoselective analysis of drugs and metabolites. Electrophoresis 2001; 22: 3308-3315.
24. Chu S and Metcalfe ChD. Analysis of paroxetine, fluoxetine and norfluoxetine in fish tissues using pressurized liquid extraction, mixed mode solid phase extraction cleanup and liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 2007; 1163: 112-118.
25. Cooke RG, Warsh JJ, Stancer HC, Reed KL and Persad E. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clinical Pharmacology and Therapeutics 1984; 36: 343-349.
26. Coulter C, Taruc M, Tuyay J and Moore C. Antidepressant drugs in oral fluid using liquid chromatography-tandem mass spectrometry. Journal of Analytical Toxicology 2010; 34: 64-72.
27. Crewe HK, Lennard MS, Tucker GT, Woods FR and Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology 1992; 34: 262-265.
28. Cutroneo P, Beljean M, Luu RPT and Siouffi AM. Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography. Journal of Pharmaceutical Biomedical Analysis 2006; 41: 333-340.
29. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S and Linnoila M. Coadministration of fluvoxamine increases serum concentrations of haloperidol. Journal of Clinical Psychopharmacology 1994; 14: 340-343.
30. de Castro A, del Mar Ramírez Fernandez M, Laloup M, Samyn N, De Boeck G, Wood M, Maes V and López-Rivadulla M. High-throughput on-line solid-phase extraction-liquid chromatography-tandem mass spectrometry method for the simultaneous analysis of 14 antidepressants and their metabolites in plasma. Journal of Chromatography A 2007; 1160: 3-12.
31. de Castro A, Concheiro M, Quintela O, Cruz A and López-Rivadulla M. LC-MS/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma. Study of correlation between venlafaxine in both matrices. Journal of Pharmaceutical and Biomedical Analysis 2008; 48: 183-193.
32. de Freitas DF, Dobrovolskin Porto CE, Vieira EP, de Siqueira MEPB. Three-phase, liquid-phase microextraction combined with high performance liquid chromatography-fluorescence detection for the simultaneous determination of fluoxetine and norfluoxetine in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 170-177.
33. Déglon J, Lauer E, Thomas A, Mangin P and Staub Ch. Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. Analytical and Bioanalytical Chemistry 2010; 396: 2523-2532.
34. de Santana FJM and Bonato PS. Enantioselective analysis of mirtazapine and its two major metabolites in human plasma by liquid chromatography-mass spectrometry after three-phase liquid-phase microextraction. Analytica Chimica Acta 2008a; 606: 80-91.
35. de Santana FJM, Lanchote VL and Bonato PS. Capillary electrophoretic chiral determination of mirtazapine and its main metabolites in human urine after enzymatic hydrolysis. Electrophoresis 2008b; 29: 3924-3932.
36. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry 1994; 55: 38-45.
37. Djordjevic S, Kovacevic I, Miljkovic B, Vuksanovic J and Pokrajac M. Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. II Farmaco 2005; 60: 345-349.
38. Duverneuil C, De la Grandmaison GL, De Mazancourt P and Alvarez JC. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Therapeutic Drug Monitoring 2003; 25: 565-573.
39. Eap CB and Baumann P. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. Journal of Chromatography B 1996; 686: 51-63.
40. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical Pharmacokinetics 1995; 29: 442-450.
41. Espinosa Bosch M, Ruiz Sánchez AJ, Sánchez Rojasc F and Bosch Ojeda C. Analytical methodologies for the determination of sertraline. Journal of Pharmaceutical and Biomedical Analysis 2008; 48: 1290-1302.
42. Fanali S, Aturki Z, Kasicka V, Raggi MA and D'Orazio G. Enantiomeric separation of mirtazapine and its metabolites by nano-liquid chromatography with UV-absorption and mass spectrometric detection. Journal of Separation Science 2005; 28: 1719-1728.
43. Ferry DG, Caplan NB and Cubeddu LX. Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. Journal of Pharmaceutical Sciences 1986; 75: 146-149.
44. Fournier T, Medjoubi-N N and Porquet D. Alpha-1-acid glycoprotein. Biochimica et Biophysica Acta Protein Structure and Molecular Enzymology 2000; 1482: 157-171.
45. Frahnert Ch, Rao ML and Grasmäder K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring Journal of Chromatography B 2003; 794: 35-47.
46. Fukushima T, Naka-aki E, Guo X, Li F, Vankeirsbilck T, Baeyens WRG, Imai K and Toyo'oka T. Determination of fluoxetine and norfluoxetine in rat brain microdialysis samples following intraperitoneal fluoxetine administration. Analytica Chimica Acta 2004; 522: 99-104.
47. Fuller RW, Hemrick-Luecke SK, Littefield S and Audia JE. Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1995; 19: 135-149.
48. Gaulier JM, Marquet P, Lacassie E, Desroches R and Lachatrea G. High-performance liquid chromatographic determination of tianeptine in plasma applied to pharmacokinetic studies. Journal of Chromatography B 2000; 748: 407-414.
49. Gronewold A, Dettling A, Haffner HT and Skopp G. Doxepin and nordoxepin concentrations in body fluids and tissues in doxepin associated deaths. Forensic Science International 2009; 190: 74-79.
50. Guo X, Fukushima T, Li F and Imai K. Determination of fluoxetine and norfluoxetine in rat plasma by HPLC with pre-column derivatization and fluorescence detection. Biomedical Chromatography 2003; 17: 1-5.
51. Halvorsen TG, Pedersen-Bjergaard S and Rasmussen KE. Liquid-phase microextraction and capillary electrophoresis of citalopram, an antidepressant drug. Journal of Chromatography A 2001; 909: 87-93.
52. Harvey AT and Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. Journal Clinical of Psychopharmacology 1996; 16: 273-285.
53. Hefnawy MM and Aboul-Enein HY. Fast high-performance liquid chromatographic analysis of mianserin and its metabolites in human plasma using monolithic silica column and solid phase extraction. Analytica Chimica Acta 2004; 504: 291-297.
54. Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A, Suri R, Leight K and Fukuchi A. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biological Psychiatry 2001; 50: 775-782.
55. Hendset M, Haslemo T, Rudberg I, Refsum H and Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006; 39: 121-127.
56. Hiemke Ch and Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology and Therapeutics 2000; 85: 11-28.
57. Horst WD, Sheldon H and Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Journal of Affective Disorders 1998; 51: 237-254.
58. Hoskins JM, Gross AS, Shenfield GM and Rivory LP. High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma. Journal of Chromatography B 2001a: 754: 319-326.
59. Hoskins JM, Shenfield GM and Gross AS. A modified HPLC method for rapid detection of moclobemide and its N-oxide metabolite in human urine. Journal of Liquid Chromatography and Related Technologies 2001b; 24: 521-529.
60. Hotopf M, Lewis G and Normand C. Are SSRIs a cost-effective alternative to tricyclics? British Journal of Psychiatry 1996; 168: 404-409.
61. Ignjatovic AR, Nikolic K, Miljkovic B, Pokrajac M, Agbaba D and Prostran M. Determination of moclobemide and its metabolites in human plasma by SPE-HPLC-UV: evaluation of critical experimental conditions and QSRR study. Journal of Liquid Chromatography and Related Technologies, 2009; 32: 2080-2096.
62. Israili ZH and Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metabolism Reviews 2001; 33: 161-235.
63. Ivandini TA, Sarada BV, Terashima C, Rao TN, Tryk DA, Ishiguro H, Kubota Y and Fujishima A. Electrochemical detection of tricyclic antidepressant drugs by HPLC using highly boron-doped diamond electrodes. Journal of Electroanalytical Chemistry 2002; 521: 117-126.
64. Jemal M, Ouyang Z, Zhao W, Zhu M and Wu WW. A strategy for metabolite identification using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability. Rapid Communications in Mass Spectrometry 2003; 17: 2732-2740.
65. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE and Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology 1996; 51: 73-78.
66. Kaliszan R and Baczek T. QSAR in chromatography: quantitative structure-retention relationships (QSRR). Recent Advances in QSAR Studies: Methods and Applications 2010; 8: 223-259.
67. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911-918.
68. Kerr GW, McGuffie AC and Wilkie S. Tricyclic antidepressant overdose: a review. Emergency Medicine Journal 2001; 18: 236-241.
69. Kingbäck M, Josefsson M, Karlsson L, Ahlner J, Bengtsson F, Kugelberg FC and Carlsson B. Stereoselective deteremination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction. Journal of Pharmaceutical and Biomedical Analysis 2010; doi: 10.1016/j.jpba.2010.03.043.
70. Kirchherr H and Kühn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. Journal of Chromatography B 2006; 843: 100-113.
71. Koski A, Sistonen J, Ojanpera I, Gergov M, Vuori E and Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Science International 2006; 158: 177-183.
72. Kovacevic I, Pokrajac M, Miljkovic B, Jovanovic D and Prostran M. Comparison of liquid chromatography with fluorescence detection to liquid chromatography-mass spectrometry for the determination of fluoxetine and norfluoxetine in human plasma. Journal of Chromatography B 2006; 830: 372-376.
73. Kratochwil NA, Huber W, Muller F, Kansy M and Gerber PR. Predicting plasma protein binding of drugs: a new approach. Biochemical Pharmacology 2002; 64: 1355-1374.
74. Labat L, Deveaux M, Dallet P and Dubost J.P. Separation of new antidepressants and their metabolites by micellar electrokinetic capillary chromatography. Journal of Chromatography B 2002; 773:17-23.
75. Lacassie E, Gaulier JM, Marquet P, Rabatel JF and Lachátre G. Methods for the determination of seven selective serotonin reuptake inhibitors and three active metabolites in human serum using high-performance liquid chromatography and gas chromatography. Journal of Chromatography B 2000; 742: 229-238.
76. Lajeunesse A, Gagnon C and Sauvé S. Determination of basic antidepressants and their N-desmethyl metabolites in raw sewage and wastewater using solid-phase extraction and liquid chromatography-tandem mass spectrometry. Analytical Chemistry 2008; 80: 5325-5333.
77. Lane EA. Renal function and the disposition of antidepressants and their metabolites. Psychopharmacology Bulletin 1991; 27: 533-540.
78. Lasher TA, Fleishaker JC, Steenwyk RC and Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991; 104: 323-327.
79. Leinonen E, Koponen HJ and Lepola U. Paroxetine increases serum trimipramine concentration. A report of two cases. Human Psychopharmacology 1995; 10: 345-347.
80. Liu W, Cai H and Li H. High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. Journal of Chromatography B 2007a; 850: 405-411.
81. Liu W, Wang F and Li H. Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in human plasma by HPLC-ESI/MS using a vancomycin chiral column. Journal of Chromatography B 2007b; 850: 183-189.
82. Llerena A, Dorado P, Berecz R, González A, Norberto MJ, de la Rubia A and Macarena Cáceres M. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. Journal of Chromatography B 2003; 783: 25-31.
83. Madej K and Kościelniak P. Review of analytical methods for identification and determination of PHEs and tricyclic antidepressants. Critical Reviews in Analytical Chemistry, 2008; 38: 50-66.
84. Mandrioli R, Pucci V, Sabbioni C, Bartoletti C, Fanali S and Raggi MA. Enantioselective determination of the novel antidepressant mirtazapine and its active demethylated metabolite in human plasma by means of capillary electrophoresis. Journal of Chromatography A 2004; 1051: 253-260.
85. Mandrioli R, Mercolini L, Ghedini N, Bartoletti C, Fanali S and Raggi MA. Determination of the antidepressant mirtazapine and its two main metabolites in human plasma by liquid chromatography with fluorescence detection. Analytica Chimica Acta 2006a; 556: 281-288.
86. Mandrioli R, Saracino MA, Ferrari S, Domenico B, Kenndler E, Raggi MA. HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma. Journal of Chromatography B 2006b; 836: 116-119.
87. Mandrioli R, Mercolini L, Cesta R, Fanali S, Amore M and Raggi MA. Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection. Journal of Chromatography B 2007; 856: 88-94.
88. Mao Y, Huang MQ, Xia YQ and Jemal M. High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 1808-1819.
89. Martínez MA, Sánchez de la Torre C and Almarza E. Simultaneous determination of viloxazine, venlafaxine, imipramine, desipramine, sertraline, and amoxapine in whole blood: comparison of two extraction/cleanup procedures for capillary gas chromatography with nitrogen-phosphorus detection. Journal of Analytical Toxicology 2002; 26: 296-302.
90. Martínez MA, Sánchez de la Torre C and Almarza E. A comparative solid-phase extraction study for the simultaneous determination of fluoxetine, amitriptyline, nortriptyline, trimipramine, maprotiline, clomipramine, and trazodone in whole blood by capillary gas-liquid chromatography with nitrogen-phosphorus detection. Journal of Analytical Toxicology 2003; 27: 353-358.
91. Matoga M, Pehourcq F, Titier K, Dumora F and Jarry C. Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma Application to management of acute intoxications. Journal of Chromatography B 2001; 760: 213-218.
92. Maurer HH and Bickeboeller-Friedrich J. Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. Journal of Analytical Toxicology 2000; 24: 340-347.
93. Meng QH and Gauthier D. Simultaneous analysis of citalopram and desmethylcitalopram by liquid chromatography with fluorescence detection after solid-phase extraction. Clinical Biochemistry 2005; 38: 282-285.
94. Mercolini L, Colliva C, Amore M, Fanali S and Raggi M.A. HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2008; 47: 882-887.
95. Millán S, Goicolea MA, Sánchez A, Gómez-Caballero A, Sampedro MC, Unceta N and Barrio RJ. Stereoselective determination of demethyl- and didemethyl-citalopram in rat plasma and brain tissue by liquid chromatography with fluorescence detection using precolumn derivatization. Biomedical Chromatography 2008; 22: 265-271.
96. Misztal G, SkibiŃski R, Olajossy M and Paw B. LC determination of moclobemide and three metabolites in plasma. Journal of Pharmaceutical and Biomedical Analysis 2002; 30: 1277-1285.
97. Molander P, Thomassen A, Kristoffersen L, Greibrokk T and Lundanes E. Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma by temperature-programmed packed capillary liquid chromatography with on-column focusing of large injection volumes. Journal of Chromatography B 2001; 766: 77-87.
98. Morgan PE, Tapper J and Spencer EP. Measurement of total mirtazapine and normirtazapine in plasma/serum by liquid chromatography with fluorescence detection. Journal of Chromatography B 2003; 798: 211-215.
99. Müller C, Vogt S, Goerke R, Kordon A and Weinmann W. Identification of selected psychopharmaceuticals and their metabolites in hair by LC/ESI-CID/MS and LC/MS/MS. Forensic Science International 2000; 113: 415-421.
100. Murray CJL and Lopez AD. Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Harvard, 1996.
101. Murray CJ and Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436-1442.
102. Musa MN. Nonlinear kinetics of trimipramine in depressed patients. Journal of Clinical Pharmacology 1989; 29: 746-747.
103. Musenga A, Kenndler E, Mercolini L, Amore M, Fanali S and Raggi MA. Determination of sertraline and N-desmethylsertraline in human plasma by CE with LIF detection. Electrophoresis 2007; 28: 1823-1831.
104. Musenga A, Saracino MA, Sani G and Raggi MA. Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. Current Medicinal Chemistry 2009; 16: 1463-1481.
105. Nałecz-Jawecki G. Evaluation of the in vitro biotransformation of fluoxetine with HPLC, mass spectrometry and ecotoxicological tests. Chemosphere 2007; 70: 29-35.
106. Neilsen KK and Gram LF. Steady-state plasma levels of clomipramine and its metabolites: impact of sparteine/debrisoquine oxidation polymorphism. European Journal of Pharmacology 1992; 43: 405-411.
107. Nordin C, Bertilsson L and Siwers B. CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. British Journal of Pharmacology 1985; 20: 411-413.
108. Ohkubo T, Shimoyama R, Otani K, Yoshida K, Higuchi H and Shimizu T. High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. Analytical Sciences 2003; 19: 859-864.
109. Öhman D, Norlander B, Peterson C and Bengtsson F. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC. Therapeutic Drug Monitoring 2001; 23; 27-34.
110. Öhman D, Norlander B, Peterson C and Bengtsson F. Simultaneous determination of reboxetine and O-desethylreboxetine enantiomers using enantioselective reversed-phase high-performance liquid chromatography. Journal of Chromatography A 2002; 947: 247-254.
111. Palego L, Dell'osso L, Marazzeti D, Biondi L, Sarno N, Ciapparelli A, Giromella A, Giannaccini G, Lucacchini A and Cassano GB. Simultaneous analysis of clozapine, clomipramine and their metabolites by reversed-phase liquid chromatography. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001; 25: 519-533.
112. Patel BN, Sharma N, Sanyal M and Shrivastav PS. High throughput and sensitive determination of trazodone and its primary metabolite, m-chlorophenylpiperazine, in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2008a; 871: 44-54.
113. Patel BN, Sharma N, Sanyal M and. Shrivastav PS. Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma and its application to a bioequivalence study. Journal of Pharmaceutical and Biomedical Analysis 2008b; 47: 603-611.
114. Patel BN, Sharma N, Sanyal M and Shrivastav PS. Analysis of second-generation antidepressant drug, sertraline and its active metabolite, N-desmethyl sertraline in human plasma by a sensitive and selective liquid chromatography-tandem mass spectrometry method. Journal of Chromatography B 2009; 877: 221-229.
115. Paus E, Jonzier-Perey M, Cochard N, Eap CB and Baumann P. Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Therapeutic Drug Monitoring 2004; 26: 366-374.
116. Peterman SM, Duczak N, Kalgutkar AS, Lame ME and Soglia JR. Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements. Journal of The American Society for Mass Spectrometry 2006; 17: 363-375.
117. Piafsky KM. Disease-induced changes in the plasma binding of basic drug. Clinical Pharmacokinetics 1980; 5: 246-262.
118. Pike E, Skuterud B, Kierulf P, Bredesen JE and Lunde PKM. The relative importance of albumin, lipoproteins and orosomucoid for drug serum binding. Clinical Pharmacokinetics 1984; 9: 84-85.
119. Pistos C, Koutsopoulou M and Panderi I. A validated liquid chromatographic tandem mass spectrometric method for the determination of mirtazapine and demethylmirtazapine in human plasma: application to a pharmacokinetic study. Analytica Chimica Acta 2004; 514: 15-26.
120. Plenis A, Chmielewska A, Konieczna L and Lamparczyk H. A validated high-performance liquid chromatographic method for the determination of moclobemide and its two metabolites in human plasma and application to pharmacokinetic studies. Biomedical Chromatography 2007; 21: 958-966.
121. Preskorn SH. Reducing the risk of drug-drug interactions: a goal of rational drug development. Journal of Clinical Psychiatry 1996; 57(suppl. 1): 3-6.
122. Preskorn SH and Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. Journal of the American Medical Association 1997; 277: 1682.
123. Preskorn, SH and Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry 1991; 52(suppl 6): 23-33.
124. Preskorn, S.H and Irwin H. Toxicity of tricyclic antidepressants-kinetics, mechanism, intervention: a review. Journal of Clinical Psychiatry 1982; 43: 151-156.
125. Preskorn, SH, Alderman J, Chung M, Harrison W, Messig M and Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Journal of Clinical Psychopharmacology 1994; 14: 90-98.
126. Qin F, Li N, Qin T, Zhang Y and Li F. Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. Journal of Chromatography B 2010; 878: 689-694.
127. Raggi MA, Pucci V, Mandrioli R, Sabbioni C and Fanali S. Determination of recent antidepressant citalopram in human plasma by liquid chromatography-fluorescence detection. Chromatographia 2003; 57: 273-278.
128. Rajasekhar D, Jaswanth Kumar I and Venkateswarlu P. Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study. Biomedical Chromatography 2009; 23: 1300-1307.
129. Rakic A, Miljkovic B, Pokrajac M and Vucicevic K. High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 1416-1422.
130. Rana S, Uralets VP and Ross W. A new method for simultaneous determination of cyclic antidepressants and their metabolites in urine using enzymatic hydrolysis and fast GC-MS. Journal of Analytical Toxicology 2008; 32: 355-363.
131. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K and Gonzalez RG. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. American Journal of Psychiatry 1992; 149: 1592-1594.
132. Rodríguez Flores J, Barzas Nevado JJ, Contento Salcedo AM and Cabello Díaz MP. Development and validation method for determination of paroxetine and its metabolites by nonaqueous capillary electrophoresis in human urine. Experimental design for evaluating the ruggedness of the method Juana. Electrophoresis 2004a; 25: 454-462.
133. Rodríguez Flores J, Berzas Nevado JJ, Contento Salcedo AM and Cabello Díaz MP. Non-aqueous capillary zone electrophoresis method for the analysis of paroxetine, tamoxifen, and their main metabolites in urine. Analytica Chimica Acta 2004b; 512: 287-295.
134. Rodríguez Flores J, Berzas Nevado JJ, Castañeda Peñalvo G and Diez NM. Development and validation method for determination of fluoxetine and its main metabolite norfluoxetine by nonaqueous capillary electrophoresis in human urine. Talanta 2005a; 65: 163-171.
135. Rodríguez Flores J, Berzas Nevado JJ, Contento Salcedo AM and Cabello Díaz MP. Nonaqueous capillary electrophoresis method for the analysis of tamoxifen, imipramine and their main metabolites in urine. Talanta 2005b; 65: 155-162.
136. Romiguieres T, Pehourcq F, Matoga M, Begaud B and Jarry C. Determination of mirtazapine and its demethyl metabolite in plasma by high-performance liquid chromatography with ultraviolet detection Application to management of acute intoxication. Journal of Chromatography B 2002; 775: 163-168.
137. Rosenstein DL, Takeshita J and Nelson JC. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose. American Journal of Psychiatry 1991; 148: 807.
138. Rudaz S, Stella C, Balant-Gorgia AE, Fanali S and Veuthey JL. Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in clinical samples by capillary electrophoresis using charged cyclodextrins. Journal of Pharmaceutical and Biomedical Analysis 2000; 23: 107-115.
139. Rudorfer MV and Potter WZ. Metabolism of tricyclic antidepressants. Cellular and Molecular Neurobiology 1999; 19: 373-409.
140. Rudorfer MV, Manji HK and Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety 1994; 10: 18-46.
141. Samanidou VF, Nika K and Papadoyannis IN. HPLC as a tool in medicinal chemistry for the monitoring of tricyclic antidepressants in biofluids. Mini-Reviews in Medicinal Chemistry 2008; 8: 256-275.
142. Sampson SM. Treating depression with selective serotonin reuptake inhibitors: a practical approach. Mayo Clinic Proceedings 2001; 76: 739-744.
143. Satonin DK, McCulloch JD, Kuo F and Knadler MP. Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma Journal of Chromatography B 2007; 852: 582-589.
144. Schneider LS, Cooper TB, Severson JA, Zemplenyi T and Sloane RB. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. Journal of Clinical Psychopharmacology 1988; 8: 402-408.
145. Segura M, Ortuño J, Farré M, Pacifici R, Pichini S, Joglar J, Segura J and De la Torre R. Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. Rapid Communications in Mass Spectrometry 2003; 17: 1455-1461.
146. Shah GR, Thaker BT, Surati KR and Parabia MH. Simultaneous determination of venlafaxine and its main active metabolite O-desmethyl venlafaxine in rat plasma by LC-MS/MS. Analytical Sciences 2009; 25: 1207-1210.
147. Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Therapeutic Drug Monitoring 2004; 26: 78-84.
148. Shen WW. The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. Biological Psychiatry 1997; 41: 814-826.
149. Shimoda K, Noguchi T, Morita S, Ozeki Y, Shibasaki M, Someya T and Takahashi S. Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. Journal of Clinical Psychopharmacology 1995; 15: 175-181.
150. Shinozuka T, Terada M and Tanaka E. Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method. Forensic Science International 2006; 162: 108-112.
151. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E and Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Therapeutic Drug Monitoring 1993; 15: 243-246.
152. Staack RF and Maurer HH. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nafazodone. Journal of Analytical Toxicology 2003; 27: 560-568.
153. Sutherland FCW, Badenhorst D, de Jager AD, Scanes T, Hundt HKL, Swart KJ and Hundt AF. Sensitive liquid chromatographic-tandem mass spectrometric method for the determination of fluoxetine and its primary active metebolite norfluoxetine in human plasma. Journal of Chromatography A 2001; 914: 45-51.
154. Timmer CJ, Lohmann AAM and Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Human Psychopharmacology 1995; 10: 97-106.
155. Titier K, Castaing N, Scotto-Gomez E, Pehourcq F, Moore N and Molimard M. High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose. Therapeutic Drug Monitoring 2003; 25: 581-587.
156. Titier K, Castaing N, Le-Déodic M, Le-Bars D, Moore N and Molimard M. Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood. Journal of Analytical Toxicology 2007; 31: 200-207.
157. Tournela G, Houdretb N, Hédouina V, Deveauxa M, Gosseta D and Lhermitte M. High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. Journal of Chromatography B 2001; 761: 147-158.
158. Unceta N, Ugarte A, Sánchez A, Gómez-Caballero A, Aránzazu Goicolea M and Barrio RJ. Development of a stir bar sorptive extraction based HPLC-FLD method for the quantification of serotonin reuptake inhibitors in plasma, urine and brain tissue samples. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 178-185.
159. Vergi-Athanasiou N, Atta-Politou J and Koupparis M. Development and validation of an HPLC method, with fluorescence detection, for simultaneous determination of paroxetine and its metabolites in plasma. Journal of Liquid Chromatography and Related Technologies 2007; 30: 1641-1655.
160. Vlase L, Imre S and L Sorin Determination of fluoxetine and its N-desmethyl metabolite in human plasma by high-performance liquid chromatography. Talanta 2005; 66: 659-663.
161. Waschgler R, Hubmann MR, Conca A, Moll W and König P. Simultaneous quantification of citalopram, clozapine, fluoxetine, norfluoxetine, maprotiline, desmethylmaprotiline and trazodone in human serum by HPLC analysis. International Journal of Clinical Pharmacology and Therapeutics 2002; 40: 554-559.
162. Waschgler R, Moll W, König P and Conca A. Quantification of venlafaxine and O-desmethylvenlafaxine in human serum using HPLC analysis. International Journal of Clinical Pharmacology and Therapeutics 2004; 42: 724-728.
163. Weigmann H, Härtter S, Bagli M and Hiemke Ch. Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. European Neuropsychopharmacology 2000; 10: 401-405.
164. Wen B, Ma L and Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chemico-Biological Interactions 2008; 173: 59-67.
165. Wenzel S, Aderjan R, Mattern R, Pedal I and Skopp G. Tissue distribution of mirtazapine and desmethylmirtazapine in a case of mirtazapine poisoning. Forensic Science International 2006; 156: 229-236.
166. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR and Flood JG. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry 1993; 32: 798-804.
167. Wille SMR, Maudens KE, Van Peteghem CH and Lambert WEE. Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis. Journal of Chromatography A 2005; 1098: 19-29.
168. Wille SMR, Van Hee P, Neels HM, Van Peteghem CH and Lambert WE. Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma. Journal of Chromatography A 2007; 1176: 236-245.
169. Wille SMR, De Letter EA, Piette MHA, Van Overschelde LK, Van Peteghem CH and Lambert WE. Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. International Journal of Legal Medicine 2009; 123: 451-458.
170. Winek CL, Wahba WW, Winek CL Jr., Winek Balzer T. Drug and chemical blood-level data 2001. Forensic Science International 2001; 122: 107-123.
171. Winter ME. Basic Clinical Pharmacokinetics. 3rd ed. Applied Therapeutics: Vancouver, WA, 1994; 449.
172. Wong SY, Dellafera SS and Fernandes R. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. Journal of Chromatography 1990; 499: 601-608.
173. WoŹniakiewicz M, Wietecha-PosŁuszny R, Garbacik A and KoŚcielniak P. Microwave-assisted extraction of tricyclic antidepressants from human serum followed by high performance liquid chromatography determination. Journal of Chromatography A 2008; 1190: 52-56.
174. Wu SM, Wua HL, Kob WK and Chena SH. Determination of amitriptyline and nortriptyline in spiked plasma by capillary zone electrophoresis with β-cyclodextrin. Analytica Chimica Acta 2000; 413: 125-129.
175. Yamada M and Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004; 25: 215-221.
176. Yao M and Srinivas NR. Simultaneous quantitation of d7-nefazodone, nefazodone, d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenylpiperazine and triazole-dione in human plasma by liquid chromatographic-mass spectrometry. Biomedical Chromatography 2000; 14: 106-112.
177. Yasui-Furukori N, Inoue Y, Kaneko S and Otani K. Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 2005; 37: 121-125.
178. Yoshida H, Hidaka K, Ishida J, Yoshikuni K, Nohta H and Yamaguchi M. Highly selective and sensitive determination of tricyclic antidepressants in human plasma using high-performance liquid chromatography with post-column tris(2, 20-bipyridyl) ruthenium(III) chemiluminescence detection. Analytica Chimica Acta 2000; 413: 137-145.
179. Zhu M, Ma L, Zhang D, Ray K, Zhao W, Humphreys WG, Skiles G, Sanders M and Zhang H. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metabolism and Disposition 2006; 34: 1722-1733.